Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9612 posts found.

clinical_trial-web

Pharma deals crucial to cutting R&D costs

December 16, 2015 Research and Development GlobalData, R&D, drug development, pharma, research and development

With the average cost of getting a novel drug to market at almost $2.5 billion, and few products achieving blockbuster …
News
Monopoly board tax

Pharma companies warned on patent box changes

December 16, 2015 Research and Development R&D, patent box, pharma, research and development, tax

Proposed Government changes to legislation will require businesses to track and trace all R&D expenditure if they want to continue …
News
R&D researcher

More breakthroughs in cancer pose the question: Who pays for them?

December 16, 2015 Research and Development Cancer, drug access, immunotherapy, oncology

The molecular revolution over the last decade has done much to help turn cancer into an illness that can be …
Feature
NHS sign

NICE rejects BMS cancer drug in draft guidance

December 16, 2015 Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, NHS, NICE, lung cancer, nivolumab, non small cell lung cancer, non-small cell lung cancer, opdivo

In draft guidance, NICE has chosen not to recommend Bristol-Myers Squibb’s Opdivo for the treatment of locally advanced or metastatic …
News
Kadcyla

NICE says no to NHS funding for Kadcyla

December 16, 2015 Research and Development, Sales and Marketing Breast Cancer Now, Kadcyla, NHS, NICE, Roche, advanced breast cancer, breast cancer

NICE has turned down Roche’s application for NHS funding for Kadcyla as a treatment for a type of advanced breast …
News

Precious Cells Group appoints David Huse in expansion push

December 15, 2015 Medical Communications, Research and Development Stem cells, precious cells group

Precious Cells Group, a UK-based international provider of stem cell storage and related technologies, has announced the appointment of commercial …
Appointment
amgen_hq

Amgen buys back rights to three drugs from GSK

December 15, 2015 Research and Development, Sales and Marketing Amgen, GSK

Amgen has announced that it will reacquire the rights to three products in 48 countries from GSK, as it seeks …
News

Bristol-Myers Squibb chooses UCLA as latest research partner

December 14, 2015 Manufacturing and Production, Research and Development BMS, Bristol-Myers Squibb, University of California Los Angeles, rare malignancies, ucla

Pharma firm Bristol-Myers Squibb is entered into a new collaboration agreement with the University of California Los Angeles (UCLA) as …
News
Ablynx CEO Edwin Moses

Ablynx sets focus on pharma collaborations

December 14, 2015 Manufacturing and Production, Research and Development Ablynx, collaboration, nanobodies, partnership

Drug development companies should prioritise strategic pharma collaborations to keep up with the next wave of immuno-oncology treatments, the chief …
News
halaven

Eisai’s Halaven shown to restrict further cancer metastasis

December 11, 2015 Research and Development, Sales and Marketing Eisai, Halaven, Merck, keytruda

New data presented by Eisai supports the previously shown ability of Halaven (eribulin) to reverse epithelial-to-mesenchymal transition, the process by …
News
roche_scientists

Which are pharma’s most innovative companies?

December 11, 2015 Medical Communications, Research and Development GSK, Roche, research and development

It has been a record-breaking year for the pharmaceutical industry in terms of deals, but what about the underlying innovation …
Feature
AZ_scientist

AstraZeneca deal to delve into the secretome

December 11, 2015 Medical Communications, Research and Development AstraZeneca, MedImmune, biologics, secretome

MedImmune, the biologics research and development arm of pharma giant AstraZeneca, has signed a collaboration with Swedish universities and research …
News

NICE publishes draft guidance on two prostate cancer treatments

December 11, 2015 Medical Communications, Research and Development, Sales and Marketing Astellas, Janssen, NICE, Xtandi, Zytiga, prostate cancer

NICE has issued final draft guidance recommending Astellas Pharma’s Xtandi (enzalutamide) in prostate cancer prior to chemotherapy, but not Janssen’s …
News
xarelto

Regulators to probe Bayer’s Xarelto trial results

December 10, 2015 Medical Communications, Research and Development

Bayer’s blockbuster anticoagulant Xarelto is under scrutiny from regulators in Europe and the US, as they try to determine whether …
News
Novolog pen

Novo Nordisk files for new insulin approval

December 10, 2015 Manufacturing and Production, Research and Development, Sales and Marketing FDA, NDA, Novo Nordisk, NovoLog, diabetes, insulin aspart, new drug application

Novo Nordisk has submitted a New Drug Application (NDA) for faster-acting insulin aspart to the FDA. If successful, the Danish …
News
The Gateway to Local Adoption Series

Latest content

Kayentis and RWS partner to improve clinical trial data confidence

April 17, 2026

MHRA expands its pioneering AI Airlock programme with £3.6m funding boost

April 16, 2026

Ardena opens new US bioanalytical laboratory

April 15, 2026

Gesynta Pharma doses first patient in endometriosis phase 2 trial

April 14, 2026

Astellas Pharma’s new non-hormonal menopausal hot flush treatment Veoza can be used in the NHS, NICE says

April 13, 2026